First BCL-2 Inhibitor Approved for Mantle Cell Lymphoma

The accelerated approval of sonrotoclax makes it the first BCL-2 inhibitor cleared for relapsed or refractory mantle cell lymphoma, offering a mechanistically distinct option for patients who have tried BTK inhibitor therapy. The drug, which binds BCL-2 with more than 10-fold greater potency than venetoclax and may carry a cleaner platelet toxicity profile, is now being tested head-to-head against venetoclax in multiple phase III chronic lymphocytic leukemia trials that could reshape the treatment landscape for that disease as well.